Gail Babilonia
Papers
1
Total Citations
22
H-Index
1
About
Gail Babilonia is a distinguished researcher whose work has significantly advanced the understanding and management of prostate cancer, particularly through the lens of biomarker discovery. Her key research areas focus on improving risk stratification for active surveillance candidates, aiming to reduce unnecessary treatments while ensuring patient safety. Babilonia’s major contributions include the development of novel models that integrate expressed prostatic secretion biomarkers, such as TMPRSS2:ERG gene fusions and secretion capacity, to refine the National Comprehensive Cancer Network (NCCN) guidelines. Her 2013 study, which has garnered 22 citations, demonstrated that these biomarkers can better identify men with low-risk, organ-confined disease, offering a more precise tool for clinical decision-making. This work has profound implications for personalized oncology, helping to spare patients from aggressive therapies when surveillance is appropriate. Babilonia’s research stands out for its translational impact, bridging molecular biology and clinical practice to enhance the accuracy of prostate cancer management. Her efforts continue to shape how clinicians approach active surveillance, making her a pivotal figure in urologic oncology.
Research Focus
Key Achievements
Top Papers
- 1